Skip navigation

CALBIO2013

CALBIO2013 is a statewide conference that has a global focus on bringing together the life sciences sector in California and targeting delegates from around the world - nearly 1,100 company executives, innovators, government representatives, medical research and disease foundation representatives, university transfer officers, philanthropists and investors will attend.

. Biotechnology and pharmaceutical companies from California and globally, interested in exchange of best business and operational practices as well as non-profit/for-profit collaborations necessary for the successful commercialization of new therapies

. Investors from across the United States and abroad seeking to invest their funds in a targeted, efficient, and effective manner

. Medical research foundations and institutes that are outcomes-driven and strategic in their allocation of resources

. Thought leaders and innovators with diverse experiences and expertise all committed to expediting the research and development process

. University transfer offices focused on facilitating the transfer of university-developed research results to industry for commercial development purposes

An improved feature this year - Business Partnering:

There is no substitute for a face-to-face meeting. Business Partnering at CALBIO2013 will help attendees to maximize their time and meeting opportunities at the Conference. Once registered for the conference, attendees will be given access to an online dating tool that will allow you to perform quick and advanced searches of companies, products and individual conference attendees to best identify potential business partners. 

Cambridge Research Biochemicals to Support Preclinical Study on Treatment for Vision-Damaging Eye Disease

Under a new contract, Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrophy, a disease that typically occurs in middle age and may cause a gradual loss of vision. More »
22 May 2018

Avacta Group plc Announces Successful Outcome of “Gene Delivery” Collaboration with FIT Biotech

Avacta Group plc (AIM: AVCT), the developer of Affimer®biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy (FITBIO:FN Finland) has successfully completed a proof-of-concept study with very encouraging data, showing sustained production of Affimer molecules by the muscle tissue of mice. This was achieved from a single dosing of the Affimer DNA using the FIT technology. More »
22 May 2018

AMSBIO Launch Gene Expression Analysis Service

AMSBIO, a global provider of gene editing and personalized medicine technologies, has launched a service for high throughput gene expression analysis. More »
22 May 2018

Novogene establishes its first European Genomic Sequencing Center at The Babraham Research Campus in Cambridge, UK

Cambridge, United Kingdom – May 21, 2018: Novogene, a leading global provider of genomic services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe. More »
21 May 2018

Concept Life Sciences ranked in top 20 fastest growing UK pharma companies

PharmaTimes presents Alantra’s Fast 50 ranking of fastest growing, privately-owned pharmaceutical businesses in the UK More »
21 May 2018

Protavio Leads Efforts on Diagnostic Tools for Chronic Kidney Disease

Protavio, an expert drug and biomarker discovery solutions provider, teams up with leading scientists in Chronic Kidney Disease (CKD) and experts in proteomics to improve diagnostic tools for clinical prognosis and diagnosis of the disease. More »
21 May 2018

Coffee adulteration uncovered using new method

A new, more sensitive method for detecting the difference between arabica and cheaper, lower quality robusta coffee based on using a benchtop NMR spectrometer has been developed at the Quadram Institute on the Norwich Research Park. Testing of samples of different coffees labeled as 100% arabica found around 10% contained robusta, potentially defrauding consumers but also smallholder coffee producers in developing countries. More »
16 May 2018

Humans on a chip – the future for research and drug discovery

Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the NC3Rs combine forces to propel the UK into the race to advance organ on a chip technology More »
15 May 2018

Charles River Laboratories Expands Services for Early Discovery Screening

Charles River Laboratories (CRL) today announced the expansion of its service capabilities in early discovery screening. CRL is the first CRO to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput ADME to identify potential lead compounds in North America and Europe. More »
15 May 2018

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

Charles River Laboratories announces extension of long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research, supporting diagnosis and treatment of Parkinson’s disease. Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research. More »
15 May 2018

<< Previous   Page 1 of 39   Next >>